Double-blind, placebo-controlled lithium treatment in chemotherapy induced aplasia for AML: reduced antibiotic requirement
S Collado, D Charron, L Degos - Medical oncology and tumor …, 1988 - Springer
S Collado, D Charron, L Degos
Medical oncology and tumor pharmacotherapy, 1988•SpringerA double-blind placebo-controlled study on lithium (Li) therapy after chemotherapy-induced
bone marrow aplasia was undertaken in 53 patients with acute myeloblastic leukemia
(AML). No difference was observed between the two groups for the duration of aplasia, the
number of units of platelets or RBC transfused, the complete remission rate or the disease
free survival. However, a statistically significant reduction in the number of days of antibiotic
therapy required was found in the treated group (10.55±2.72 vs 12.73±3.60, P< 0.05).
bone marrow aplasia was undertaken in 53 patients with acute myeloblastic leukemia
(AML). No difference was observed between the two groups for the duration of aplasia, the
number of units of platelets or RBC transfused, the complete remission rate or the disease
free survival. However, a statistically significant reduction in the number of days of antibiotic
therapy required was found in the treated group (10.55±2.72 vs 12.73±3.60, P< 0.05).
Abstract
A double-blind placebo-controlled study on lithium (Li) therapy after chemotherapy-induced bone marrow aplasia was undertaken in 53 patients with acute myeloblastic leukemia (AML). No difference was observed between the two groups for the duration of aplasia, the number of units of platelets or RBC transfused, the complete remission rate or the disease free survival. However, a statistically significant reduction in the number of days of antibiotic therapy required was found in the treated group (10.55 ± 2.72 vs 12.73 ± 3.60,P < 0.05).
Springer